Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.
Autor: | Alkadimi, Munaf A, Aldawoodi, Tamarah A, Lucero, Kana T, Fierro, Maria E, Boyle, Lauren D, Mader, Michael J, Franklin, Kathleen R, Arora, Sukeshi P, Nooruddin, Zohra |
---|---|
Předmět: |
THERAPEUTIC use of antineoplastic agents
THERAPEUTIC use of monoclonal antibodies MEDICAL care of veterans VIRAL hepatitis BEVACIZUMAB SYMPTOMS TREATMENT effectiveness RETROSPECTIVE studies CHI-squared test MANN Whitney U Test DESCRIPTIVE statistics BILIRUBIN METASTASIS PHYSICIAN practice patterns MEDICAL records ACQUISITION of data ELECTRONIC health records PROGRESSION-free survival ALBUMINS HEPATOCELLULAR carcinoma NOSOLOGY OVERALL survival EVALUATION |
Zdroj: | Oncologist; May2024, Vol. 29 Issue 5, p369-376, 8p |
Abstrakt: | Purpose This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab with bevacizumab (A + B) therapy at the Veterans Health Administration (VHA). Patients and Methods Patients with advanced HCC who received first-line systemic therapy with A + B at the VHA between December 1, 2019, and March 1, 2022, were selected from electronic medical records (EMR) using ICD-9 and ICD-10 codes. Abstractors reviewed the EMR of the patients from their index date of A + B initiation until death or their last VHA visit, with the study period ending on January 31, 2023. The chi-square test was used to compare rates, and the Mann-Whitney test was used to compare medians. Results A total of 332 patients met the study criteria. The median age was 67 years; 99% were male, 63% were non-Hispanic Whites, 26% were Black, and 66% had an Eastern Cooperative Oncology Group performance status of ≥1. 84% had child Pugh score (CPS) class A, 16% had CPS classes B and C, 62% had a grade 2 albumin-bilirubin score, 56% had HCC caused by viral hepatitis, 80% had cirrhosis, and 67% had received prior local therapies. The 6-month progression-free survival (PFS) was 59%, while the 1-year PFS rate was 36%. Overall survival (OS) at 1-year was 52% in our study. Conclusion In real world, despite having similar PFS as the phase III IMbrave 150 trial, our OS at 12 months was lower (52% vs. 67%) because our study included a higher proportion of elderly patients with moderate liver dysfunction and a 40% non-White. This study provided real-world outcomes that differed from the study population in a pivotal trial. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |